Nouhad Husseini
Directeur/Membre du Conseil chez DECIBEL THERAPEUTICS, INC.
Postes actifs de Nouhad Husseini
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2011 | - |
| CHECKMATE PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 31/05/2022 | - |
| Corporate Officer/Principal | 31/05/2022 | - | |
| DECIBEL THERAPEUTICS, INC. | Directeur/Membre du Conseil | 22/09/2023 | - |
| Corporate Officer/Principal | 22/09/2023 | - |
Historique de carrière de Nouhad Husseini
Formation de Nouhad Husseini
| Princeton University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 6 |
Opérationnelle
| Corporate Officer/Principal | 3 |
| Director/Board Member | 2 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| DECIBEL THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Bourse
- Insiders
- Nouhad Husseini
- Expérience
